Introduction
Mitogen-activated protein (MAP) kinase kinase-4 (MKK4) is a dual-specificity kinase that is activated by stress and peptide growth factors. MKK4 phosphorylates c-Jun N-terminal kinase (JNK) and p38/HOG1 (Gallo and Johnson, 2002) . The MKK4 gene is located near the p53 tumor suppressor gene on chromosome 17p11.2, a region that is frequently deleted in cancer cells. Several lines of evidence initially suggested that MKK4 is a tumor suppressor gene. First, genetic alterations leading to MKK4 deletion or loss of function were found in a subset of breast and pancreatic cancer cells (Teng et al., 1997; Su et al., 1998) . Second, decreased immunohistochemical staining of MKK4 was reported to be associated with advanced-stage prostate and ovarian tumors (Kim et al., 2001; Yamada et al., 2002) . Finally, embryonic stem cells transfected with dominant-negative mutant MKK4 exhibited increased colony formation in soft agar (Cazillis et al., 2004) .
There is also evidence that MKK4 has pro-survival and oncogenic functions. In particular, targeted disruption of MKK4 resulted in embryonic death owing to defective liver formation and enhanced liver cell apoptosis (Nishina et al., 1999) . Further, MKK4 mediates survival signals in T lymphocytes (Nishina et al., 1997) and was recently shown to be oncogenic in breast and pancreatic tumors (Wang et al., 2004) . MKK4 is also a downstream mediator of K-Ras, which is frequently mutated in lung adenocarcinomas (Mitsudomi et al., 1991; Sugio et al., 1992) . In addition, lung adenocarcinomas that arose in mice as a result of mutant KRAS showed evidence of MKK4 activation (Lee et al., 2002) . Finally, MKK4 activation rescues non-small-cell lung cancer (NSCLC) cells from apoptosis induced by inhibition of phosphatidylinositol 3-kinase (Lee et al., 2003) .
The downstream mediator of MKK4, JNK, has similarly been reported to either enhance or attenuate oncogenesis in cellular models . Several studies support the role of JNK in potentiating oncogenesis. For example, tumor cell lines have been reported to have constitutively active JNK (Ip and Davis, 1998; Yang et al., 2003) , and the kinase potentiates B-cell lymphoma caused by BCR-Abl (Hess et al., 2002) . Further, the transforming potential of several oncogenes was reduced upon introduction of antisense JNK oligonucleotides or dominant-negative versions of proteins belonging to the JNK pathway (Potapova et al., 1997 (Potapova et al., , 2000 Bost et al., 1999; Hess et al., 2002; Yang et al., 2003) . In other studies, JNK maintained the transformed properties of NSCLC cells and was required for the proliferative effects of cigarette smoke on bronchial epithelial cells (Xiao and Lang, 2000; Zhong et al., 2005) . In direct contrast to these findings, JNK has also been reported to inhibit oncogenesis by potentiating apoptosis, suppressing tumor cell metastasis and inhibiting tumor formation induced by Ras .
In this study, we sought to better define the role of JNK in NSCLC by examining evidence of JNK phosphorylation in NSCLC biopsy samples and by using genetic and pharmacologic approaches to modulate JNK expression and activity in cultured cells. We concluded that JNK activation promotes lung tumorigenesis in a subset of patients, suggesting that strategies to inhibit the JNK pathway should be considered for the prevention and treatment of NSCLC.
Results

JNK is phosphorylated in NSCLC
JNK is phosphorylated at Thr183/Tyr185 by two dualspecificity kinases, MKK4 and MKK7. To investigate JNK phosphorylation in NSCLC, we first performed immunohistochemical analysis of NSCLC biopsy samples using an antibody that detects p-JNK. For these studies, we used a tissue microarray constructed from 252 randomly collected NSCLC biopsy samples. The patients' clinical variables (age, gender, ethnicity, smoking status, disease stage and duration of survival) and tumor histologic features (adenocarcinoma or squamous cell carcinoma) are summarized in Supplementary Table 1 .
Relevant negative controls (absence of primary antibody and preincubation of primary antibody with blocking peptide) confirmed the specificity of immunohistochemical staining for p-JNK ( Figure 1a ). The staining varied in intensity and extent among tumor biopsy samples and was detected in both the cytoplasmic and nuclear compartments of tumor cells (Figure 1b and c). Overall, p-JNK was detected (either cytoplasmic or nuclear staining) in 114 (45%) of the 252 tumors. Of those, p-JNK was cytoplasmic in 53 (46%) and nuclear in 103 (90%), which is consistent with previous reports that activated JNK localizes to both cytoplasmic and nuclear compartments and that nuclear translocation is a feature of p-JNK (Huang et al., 2004) . p-JNK staining was not associated with clinical variables or specific tumor histologic subtypes.
Establishment of HBE cell lines that inducibly express activated MKK4 Based on the above findings, we hypothesized that JNK activation is sufficient to confer neoplastic properties on HBE cells. To test this, we stably introduced a Flagtagged, constitutively activated form of MKK4 (MKK4-ED mutant) into BEAS-2B, an Simian virus 40 (SV40)T antigen-immortalized HBE cell line with low basal MKK4 expression (Figure 2 ). We used a doxycycline-inducible expression strategy to detect either prosurvival or proapoptotic effects. Three BEAS-2B clones (two MKK4-inducible clones and one control clone expressing luciferase) were chosen for further study.
Western blot analysis using anti-Flag antibodies demonstrated that doxycycline increased MKK4-ED expression in the two MKK4-inducible clones (C6 and C8) but not in the luciferase control ( Figure 2 ). Kinase assays revealed that MKK4-ED expression enhanced activation of JNK but not p38, which is consistent with a previous report that MKK4 activates JNK more potently than it does p38 (Nishina et al., 1997) . We subsequently used this model to investigate whether MKK4 activation is sufficient to alter the biological properties of BEAS-2B cells and to examine the role of JNK in this process.
MKK4 activation confers certain neoplastic properties on HBE cells
We investigated the effect of MKK4-ED expression on the ability of BEAS-2B cells to proliferate in monolayer cultures (Figure 3a) , to migrate across polycarbonate filters (Figure 3b ), to heal wounds on a plastic surface (Figure 3c ), to invade through Matrigel plugs ( Figure 3d ) and to form colonies in soft agar ( Figure 3e ). Doxycycline enhanced the performance of the C6 and C8 clones but not the luciferase control in all of these assays, indicating that MKK4-ED expression conferred certain malignant properties on BEAS-2B cells. We next investigated the tumorigenicity of these cell lines. C8 cells and luciferase controls were injected into the flanks of nude mice, which were treated with or without doxycycline and examined for tumor development. After 21 days of treatment, we observed no evidence of tumor formation. Thus, we conclude that MKK4 expression in BEAS-2B cells conferred certain malignant properties but, under these conditions, was not sufficient to confer tumorigenicity.
Because SV40 viral oncogenes inactivate p53 and Rb family members, we were concerned that the transformed phenotype induced by MKK4-ED depended on SV40 T-antigen expression in BEAS-2B cells. To rule this out, we studied HB56B cells, which were immortalized spontaneously without the introduction of viral oncoproteins (Reddel et al., 1988) . Doxycycline increased the proliferation, migration and invasion of HB56B cells transfected with doxycycline-inducible MKK4-ED but not luciferase (Supplementary Figure 1) . Thus, the oncogenic effects of MKK4-ED do not depend on expression of SV40T antigen.
JNK is required for HBE cell transformation by MKK4-ED
To investigate the role of JNK in HBE cell transformation by MKK4-ED, JNK was depleted from C8 cells by stably transfecting them with retroviruses expressing JNK1/2 short hairpin RNA (shRNA). Two clones of transfected cells (S1 and S2) were selected for further study. These clones had 63% and 59% reductions in JNK expression, respectively, relative to that of C8 cells and showed an attenuation of basal and doxycyclineinduced c-Jun phosphorylation despite robust increases in MKK4-ED levels ( Figure 4a ). Introduction of retroviruses expressing scrambled JNK shRNA had no discernable effect on JNK levels in C8 cells (data not shown). Doxycycline treatment of S1 and S2 cells had no detectable effect on cell proliferation (Figure 4b ), migration ( Figure 4c ) or clonogenicity (Figure 4d ), indicating that JNK is required for MKK4-ED to induce these processes in BEAS-2B cells. Interestingly, doxycycline had a minimal, but significant, effect on cell invasion in S1 and S2 cells (Figure 4e ), suggesting that MKK4-ED confers invasive properties in part through JNK-independent mechanisms. JNK activation is a proliferative signal in NSCLC cell lines Cancer cells that express constitutively activated kinases frequently depend on these kinases for proliferation, survival or both (Lynch et al., 2004; Paez et al., 2004) . We investigated a panel of NSCLC cell lines to identify those that have constitutively activated JNK. NSCLC cell lines were serum starved for 24 h to remove analysis of MKK4 and c-Jun gene loci on chromosomes 17q12 and 1p32.1, respectively. We found single-copy gain of MKK4 and c-Jun in both HCC827 and H2009 cells, a minimal change that is unlikely to account for the increased expression of MKK4 and c-Jun observed in these cell lines.
We investigated the role of JNK in NSCLC cell proliferation and survival using SP600125, a JNK-specific kinase inhibitor. We first examined the specificity of SP600125 for JNK using C8 and its JNK-depleted derivatives S1 and S2. Treatment of C8 cells for 24 h with SP600125 inhibited c-Jun phosphorylation (half-maximal inhibitory concentration, 4.0 mM) in a dose-dependent manner (Figure 6a) . Treatment with 4.0 mM SP600125 inhibited the proliferation of C8 cells but not S1 or S2 cells (Figure 6b ), demonstrating that JNK is required for the antiproliferative effect of SP600125.
We then treated HCC827 and H2009 cells with SP600125 and examined cell numbers and the phosphorylation of c-Jun. In both cell lines, cell numbers and c-Jun phosphorylation decreased in a dose-dependent manner (Figure 6c and d) . The half-maximal inhibitory concentration values, based on cell numbers, were 13.5 mM for HCC827 cells and 12.5 mM for H2009 cells. At these doses, p-c-Jun levels were 50% lower based on densitometric analysis of Western blots of both cell lines. After treatment with SP600125, no evidence of apoptosis was revealed by Hoechst staining to identify cells with nuclear condensation and fragmentation or by Western blotting for cleavage of caspase-3 and poly (ADP-ribose) polymerase (data not shown). In contrast, the SP600125 IC 50 value for H157 cells, which have low JNK phosphorylation, was 22.6 mM. Thus, compared to a NSCLC cell line with low JNK activity, the two NSCLC cell lines with constitutive JNK activation had greater sensitivity to SP600125 and depended on JNK for cell proliferation but not for survival.
Discussion
We previously showed that MKK4 activation rescues NSCLC cells from apoptosis induced by phosphatidylinositol 3-kinase inhibition (Lee et al., 2003) , indicating a pro-survival effect of MKK4 in NSCLC cells. Here we explored the role of JNK, a downstream mediator of MKK4, in NSCLC and found evidence to support its role in tumor promotion. First, JNK was phosphorylated in a subset of NSCLC biopsy samples. Second, the introduction of an upstream activator of JNK, MKK4, conferred neoplastic properties on HBE cells. Third, JNK depletion reversed the oncogenic effects of MKK4 activation in HBE cells. Fourth, JNK was constitutively active in two NSCLC cell lines, and these cells were sensitive to pharmacologic inhibition of JNK. Thus, we conclude that JNK is activated in a subset of NSCLC biopsy samples and promotes oncogenesis in the bronchial epithelium. Whereas we found no association of intratumoral p-JNK staining with pathologic stage or patient survival, p-JNK staining was reported to correlate with early-stage disease (Vicent et al., 2004) . One potential explanation for the disparate outcomes of the two studies is the difference between the patient populations. In studies of Vicent et al. (2004) the patients were fairly equally split between those with localized (stage I/II) and advanced (stage III/IV) disease, whereas, in ours, the patients had primarily localized disease. The inclusion of both early-and late-stage disease patients in studies of Vicent et al. (2004) enhanced the power of this study to detect stage-associated differences in p-JNK staining. Further, whereas we found no association of p-JNK staining with patient survival, Vicent et al. (2004) reported that staining for MKP-1, a MAP kinase phosphatase, correlated with prolonged survival. Although the reason for this difference is not clear, one possibility is related to the ability of MKP-1 to dephosphorylate extracellular signal-regulated kinase, JNK and p38. The improved prognosis associated with MKP-1 expression could be mediated by any or all of these MAP kinases.
Although findings reported here support a role for JNK in lung tumorigenesis, the mechanisms by which this pathway is activated in NSCLC have not been elucidated. One possibility is that JNK is activated by upstream kinases rendered constitutively active by somatic mutations. For example, somatic mutations in KRAS and EGFR occur in subsets of NSCLC (Mitsudomi et al., 1991; Sugio et al., 1992; Lynch et al., 2004; Paez et al., 2004) and activate a variety of kinase pathways, including those regulating JNK. However, correlative studies performed on tumors in the tissue microarray revealed no association between p-JNK staining and the presence of somatic mutations in KRAS or EGFR (Supplementary Table 2 ). Alternatively, JNK phosphorylation might be increased in tumors by somatic mutations in the MKK4 kinase domain, which were recently identified in NSCLC and colon cancer (Davies et al., 2005; Parsons et al., 2005) . The biochemical properties of the mutant MKK4 gene product have not been reported. Given the evidence reported here, studies are currently under way to examine the incidence of MKK4 gene mutations in NSCLC and the biochemical properties and oncogenic potential of the mutant MKK4 gene product.
One striking finding from this study was the diversity of biological properties regulated by the introduction of constitutively activated MKK4 in BEAS-2B cells, including cell proliferation, migration, invasion and clonogenicity. These phenotypic changes were attenuated by the introduction of JNK shRNA, indicating that JNK is largely responsible for these effects of MKK4-ED. Downstream mediators of JNK have been identified that modulate these cellular functions. For example, JNK localizes to focal adhesions and phosphorylates paxillin, an adapter protein involved in adhesion organization and cell migration (Huang et al., 2003) . JNK also phosphorylates c-Jun, a component of the activator protein-1 (AP-1) transcription factor, which promotes cell-cycle progression by activating the expression of cyclin D1 (Bakiri et al., 2000) . AP-1 also regulates the expression of matrix metalloproteinases, collagenase, osteonectin, plasminogen activator inhibitor and uroplasminogen activator receptor, which are involved in the breakdown of the extracellular matrix, a crucial event in cancer cell invasion (Briggs et al., 2002; Liu et al., 2004; Milde-Langosch et al., 2004; Bachmeier et al., 2005; Belguise et al., 2005; Kim et al., 2005; Lu et al., 2005; Rangaswami et al., 2005) . In addition, JNK increases the expression of Bcl2, a pro-survival signal that is a common feature of cancer cells (Hess et al., 2002) . Thus, JNK regulates a variety of cellular functions by activating a diverse set of downstream effectors. The central role of MKK4 and JNK in cellular transformation makes them attractive as targets in cancer prevention and treatment. However, these kinases can either potentiate or inhibit tumorigenesis; thus, strategies to inhibit these kinases in cancer patients may be either efficacious or injurious and, thus, should be approached cautiously. To better select subsets of patients who would benefit from such approaches will require a better understanding of JNK's role in the context of specific genetic mutations. For example, JNK is reported to act as a tumor suppressor in the setting of KRAS mutations , whereas our findings would predict that JNK promotes tumorigenesis in the setting of activating mutations in MKK4. Selective inhibitors of JNK are under investigation in Phase I clinical trials for the treatment of cancer and inflammatory diseases. Selective inhibitors of MKK4 are not currently available. Developing smallmolecule inhibitors against the MKK4 kinase domain would be facilitated by the resolution of the MKK4 protein structure, which has not yet been reported. Selective inhibitors of the MKK1 kinase domain, which is highly conserved among MKK family members, are in Phase II clinical trials in cancer patients (Lorusso et al., 2005) , suggesting that the development of MKK4 antagonists is feasible.
Materials and methods
Cell lines and culture conditions
The immortalized HBE cell lines BEAS-2B (Reddel et al., 1988) and HB56B (Reddel et al., 1991) were gifts from Dr Curt Harris (National Cancer Institute) and Dr Gary Stoner (Ohio State University), respectively, and were cultured in keratinocyte serum-free medium (Invitrogen, Carlsbad, CA, USA) supplemented with bovine pituitary extract, epidermal growth factor, 100 U/ml penicillin and 100 mg/ml streptomycin at 371C in the presence of 5% CO 2 . PT67 fibroblasts (Clontech, Mountain View, CA, USA) were maintained in Dulbecco's Modified Essential Media supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. The NSCLC cell lines H1299, HCC827, H2009, H2279, H226Br, H622 and H157 (American Type Culture Collection, Bethesda, MD, USA) and were maintained in Rosewell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were cultured at 371C in the presence of 5% CO 2 .
Reagents and antibodies Doxycycline was purchased from BD Biosciences (Palo Alto, CA, USA). SP600125, a JNK-specific kinase inhibitor, was provided by Celgene Pharmaceuticals (San Diego, CA, USA). Staurosporine was purchased from Chemicon (Temecula, CA, USA). Antibodies against Thr183/Tyr185-phosphorylated stress-activated protein kinase/JNK (p-JNK), Ser63-phosphorylated c-Jun (p-c-Jun), Thr180/Tyr182-phosphorylated p38 (p-p38), Thr69/Thr71-phosphorylated activating transcription factor-2 (p-ATF-2), total JNK, total MKK4, total c-Jun, total p38, total ATF-2, cleaved caspase-3 and poly-(ADP-ribose) polymerase were purchased from Cell Signaling Technology (Beverly, MA, USA). We purchased a rabbit polyclonal p-JNK antibody from Upstate Biotechnology (Charlottesville, VA, USA) for immunoblotting experiments. Antibodies against Flag and b-actin were purchased from Sigma Aldrich (St Louis, MO, USA). Non-radioactive kinase assay kits for JNK and p38 were purchased from Cell Signaling Technology. Construction of tissue microarrays, mutational analysis of tumor samples, characterization of NSCLC cell lines, generation and characterization of stable transfectants from retroviruses and statistical analysis. Details pertinent to these experiments are located in Supplementary Materials.
